(Q35041910)

6 August 2017

0 references

1 reference

https://doi.org/10.1002/14651858.CD003831.pub2

1 reference

29 December 2023

title

Celecoxib for rheumatoid arthritis. (English)

1 reference

6 August 2017

0 references

8

P Tugwell

1 reference

6 August 2017

S Garner

1

1 reference

6 August 2017

D Fidan

2

1 reference

6 August 2017

R Frankish

3

1 reference

6 August 2017

M Judd

4

1 reference

6 August 2017

B Shea

5

1 reference

6 August 2017

T Towheed

6

1 reference

6 August 2017

G Wells

7

1 reference

6 August 2017

1 January 2002

1 reference

Cochrane Database of Systematic Reviews

6 August 2017

1 reference

6 August 2017

4

1 reference

6 August 2017

CD003831

1 reference

Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison.

6 August 2017

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003831

Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003831

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003831

The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003831

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003831

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003831

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003831

21 January 2018

Cyclooxygenases 1 and 2

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003831

Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003831

Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial

21 January 2018

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD003831

Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD003831

Evaluation of health-related quality of life of rheumatoid arthritis patients treated with celecoxib.

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD003831

Analgesia and non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the hip.

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD003831

Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD003831

Non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the knee

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD003831

ACR 20: clinical or statistical significance?

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD003831

Rofecoxib for the treatment of rheumatoid arthritis

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD003831

Identifiers

DOI

10.1002/14651858.CD003831

1 reference

6 August 2017

1 reference